MX2023001851A - Neoantigenos ras y usos de los mismos. - Google Patents
Neoantigenos ras y usos de los mismos.Info
- Publication number
- MX2023001851A MX2023001851A MX2023001851A MX2023001851A MX2023001851A MX 2023001851 A MX2023001851 A MX 2023001851A MX 2023001851 A MX2023001851 A MX 2023001851A MX 2023001851 A MX2023001851 A MX 2023001851A MX 2023001851 A MX2023001851 A MX 2023001851A
- Authority
- MX
- Mexico
- Prior art keywords
- epitope
- protein encoded
- hla allele
- compositions
- binds
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Se describen composiciones y métodos para la preparación de composiciones de células T y usos de las mismas, incluidos métodos para el tratamiento del cáncer en un sujeto que lo necesite por la administración de células T inducidas con péptidos que comprenden como mínimo uno de los epítopos KRAS que tienen una secuencia GACGVGKSA (SEQ ID NO: 1) que se une a una proteína codificada por un alelo HLA-C03:04; o que tiene una secuencia GAVGVGKSA (SEQ ID NO: 2) que se une a una proteína codificada por un alelo HLA-C03:03, en donde la proteína respectiva codificada por el alelo HLA se expresa en una célula del sujeto. También se incluyen composiciones inmunogénicas que comprenden péptidos que comprenden un epítopo descrito anteriormente, o células presentadoras de antígeno cargadas con los péptidos que comprenden el epítopo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063065346P | 2020-08-13 | 2020-08-13 | |
PCT/US2021/045808 WO2022036142A2 (en) | 2020-08-13 | 2021-08-12 | Ras neoantigens and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001851A true MX2023001851A (es) | 2023-04-26 |
Family
ID=80248174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001851A MX2023001851A (es) | 2020-08-13 | 2021-08-12 | Neoantigenos ras y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230398218A1 (es) |
EP (1) | EP4196153A2 (es) |
JP (1) | JP2023539055A (es) |
KR (1) | KR20230107206A (es) |
CN (1) | CN116507354A (es) |
AU (1) | AU2021325082A1 (es) |
BR (1) | BR112023002724A2 (es) |
CA (1) | CA3189269A1 (es) |
CL (1) | CL2023000426A1 (es) |
CO (1) | CO2023002959A2 (es) |
CU (1) | CU20230010A7 (es) |
IL (1) | IL300565A (es) |
MX (1) | MX2023001851A (es) |
WO (1) | WO2022036142A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE342730T1 (de) | 1992-08-07 | 2006-11-15 | Pharmexa Inc | Hla bindepeptide und ihre verwendungen |
AU6359494A (en) | 1993-03-05 | 1994-09-26 | Epimmune, Inc. | Hla-a2.1 binding peptides and their uses |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
CN116693695A (zh) | 2017-02-12 | 2023-09-05 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
KR20230008254A (ko) | 2017-11-08 | 2023-01-13 | 바이오엔테크 유에스 인크. | T 세포 제조 조성물 및 방법 |
JP7480064B2 (ja) * | 2018-02-27 | 2024-05-09 | グリットストーン バイオ インコーポレイテッド | パンアレルモデルによる新生抗原の特定方法 |
CN112638404A (zh) * | 2018-06-19 | 2021-04-09 | 百欧恩泰美国公司 | 新抗原及其用途 |
GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
-
2021
- 2021-08-12 MX MX2023001851A patent/MX2023001851A/es unknown
- 2021-08-12 CA CA3189269A patent/CA3189269A1/en active Pending
- 2021-08-12 KR KR1020237008657A patent/KR20230107206A/ko unknown
- 2021-08-12 IL IL300565A patent/IL300565A/en unknown
- 2021-08-12 CN CN202180070306.2A patent/CN116507354A/zh active Pending
- 2021-08-12 US US18/007,096 patent/US20230398218A1/en active Pending
- 2021-08-12 EP EP21856745.1A patent/EP4196153A2/en active Pending
- 2021-08-12 WO PCT/US2021/045808 patent/WO2022036142A2/en active Application Filing
- 2021-08-12 CU CU2023000010A patent/CU20230010A7/es unknown
- 2021-08-12 BR BR112023002724A patent/BR112023002724A2/pt unknown
- 2021-08-12 AU AU2021325082A patent/AU2021325082A1/en active Pending
- 2021-08-12 JP JP2023509798A patent/JP2023539055A/ja active Pending
-
2023
- 2023-02-10 CL CL2023000426A patent/CL2023000426A1/es unknown
- 2023-03-10 CO CONC2023/0002959A patent/CO2023002959A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021325082A1 (en) | 2023-04-20 |
KR20230107206A (ko) | 2023-07-14 |
US20230398218A1 (en) | 2023-12-14 |
JP2023539055A (ja) | 2023-09-13 |
CN116507354A (zh) | 2023-07-28 |
CL2023000426A1 (es) | 2023-09-08 |
EP4196153A2 (en) | 2023-06-21 |
CA3189269A1 (en) | 2022-02-17 |
CO2023002959A2 (es) | 2023-06-20 |
WO2022036142A2 (en) | 2022-02-17 |
BR112023002724A2 (pt) | 2023-05-02 |
WO2022036142A3 (en) | 2022-03-24 |
CU20230010A7 (es) | 2023-12-07 |
IL300565A (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
CN110078813B (zh) | 免疫原性wt-1肽和其使用方法 | |
NZ750005A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
EP4269560A3 (en) | Modified epidermal growth factor receptor peptides for use in genetically-modified cells | |
EP4219690A3 (en) | Methods of cancer treatment using activated t cells | |
DE602005015990D1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
MX2021005372A (es) | Composiciones de linfocitos t con propiedades fenotípicas mejoradas. | |
JP2019517508A5 (es) | ||
BR112012018457A2 (pt) | peptídeos melk modificados e vacinas contendo os mesmos | |
WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
Woodruff et al. | Synergistic inhibition of mammary carcinoma transplants in A-strain mice by antitumour globulin and C. parvum | |
WO2021163562A3 (en) | Compositions and methods comprising splicing-derived antigens for treating cancer | |
Miao et al. | CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model | |
MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
Mougel et al. | Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling | |
AU2018347511A8 (en) | Periodontitis vaccine and related compositions and method of use | |
MX2023002080A (es) | Vector de poxviridae recombinante que expresa moleculas coestimuladoras. | |
BR112021018684A2 (pt) | Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+ | |
Kellen et al. | Effects of antibodies to choriogonadotropin in malignant growth: II. Solid transplantable rat tumors |